Testing effectiveness (Phase 2)Study completedNCT02387099What this trial is testingDose EScalation Induction of EvERolimusWho this might be right forBreast CancerHormone Receptor Positive Tumor GBG Forschungs GmbH 156
Large-scale testing (Phase 3)Ended earlyNCT00097344What this trial is testingThe CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerWho this might be right forBreast NeoplasmsNeoplasms, Hormone-Dependent Intarcia Therapeutics 842
Not applicableStudy completedNCT01273415What this trial is testingUsefulness of Ki67 Index in Hormone Receptor-positive Breast CancerWho this might be right forBreast Cancer Samsung Medical Center 1,070
Testing effectiveness (Phase 2)UnknownNCT00687648What this trial is testingCyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast CancerWho this might be right forBreast Cancer National Cancer Centre, Singapore 70
Early research (Phase 1)Study completedNCT02219789What this trial is testingAlisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryWho this might be right forEstrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+3 more Mayo Clinic 10
Testing effectiveness (Phase 2)Study completedNCT01068704What this trial is testingEfficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast CancerWho this might be right forBreast Cancer Bristol-Myers Squibb 4
Early research (Phase 1)Looking for participantsNCT05098210What this trial is testingPersonalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerWho this might be right forAnatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more Fred Hutchinson Cancer Center 25
Large-scale testing (Phase 3)Active Not RecruitingNCT03820830What this trial is testingPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerWho this might be right forBreast Cancer Recurrent ETOP IBCSG Partners Foundation 405
Early research (Phase 1)Study completedNCT00006368What this trial is testingYttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerWho this might be right forBrain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Ended earlyNCT02273752What this trial is testingPharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerWho this might be right forEstrogen Receptor-positive Breast CancerGastrinomaGlucagonoma+16 more Emory University 2
Testing effectiveness (Phase 2)Study completedNCT00010010What this trial is testingExemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast CancerWho this might be right forBreast Cancer NYU Langone Health
Testing effectiveness (Phase 2)Looking for participantsNCT07498478What this trial is testingEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior TreatmentWho this might be right forBreast Cancer TransThera Sciences (Nanjing), Inc. 94
Early research (Phase 1)Study completedNCT02088684What this trial is testingStudy of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast CancerWho this might be right forBreast Cancer Novartis Pharmaceuticals 70
Large-scale testing (Phase 3)Not Yet RecruitingNCT07391774What this trial is testingTesting Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialWho this might be right forAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8+2 more National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT00379197What this trial is testingPhase II of Naltrexone in Hormone-Refractory Metastatic Breast CancerWho this might be right forBreast Cancer Masonic Cancer Center, University of Minnesota 13
Large-scale testing (Phase 3)Looking for participantsNCT07190443What this trial is testingAdjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)Who this might be right forBreast CancerLocoregional RecurrenceAbemaciclib+1 more Japanese Foundation for Cancer Research 290
Testing effectiveness (Phase 2)Ended earlyNCT03430466What this trial is testingAnti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast CancerWho this might be right forBreast Cancer Kyoto Breast Cancer Research Network 1
Large-scale testing (Phase 3)Active Not RecruitingNCT02763566What this trial is testingAbemaciclib (LY2835219) in Participants With Breast CancerWho this might be right forBreast Cancer Eli Lilly and Company 463
Testing effectiveness (Phase 2)Study completedNCT00941330What this trial is testingExemestane or Docetaxel-Cytoxan in Low Recurrence Score CancersWho this might be right forBreast Cancer Emory University 31
Testing effectiveness (Phase 2)Ended earlyNCT03330405What this trial is testingJavelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsWho this might be right forAvelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors Pfizer 223